It remains inconclusive whether the use of nonsteroidal anti-inflammatory drugs (NSAIDs) increases the risk of atrial fibrillation (AF), especially in middle-aged Asian populations. In this study, we evaluated the association between NSAID use and the risk of AF in a nationwide population-based study of middle-aged individuals in Taiwan.
Introduction
Atrial fibrillation (AF), a common cardiac arrhythmia, affects approximately 0.5% of the general population, but more than 6% of the elderly population [1, 2] . It is noteworthy that the prevalence of AF has been rising during the past decades [3] . Several studies have reported that AF is associated with an elevated risk of cardiovascular or cerebrovascular diseases and death [4] [5] [6] . The underlying mechanisms that lead to the development of AF remain unclear, but recent studies have suggested that inflammation may precede the pathogenesis of AF [7, 8] .
Previous studies have documented a positive association between the use of non-steroidal anti-inflammatory drugs (NSAIDs) and the risk of AF, but limited studies have been conducted in Asian populations [9] [10] [11] [12] [13] . NSAIDs are cyclooxygenase (COXs)-mediated inhibitors, and NSAID mechanisms are related to the inhibition of the formation of prostaglandins, prostacyclins and thromboxanes [14, 15] . For these reasons, at present, NSAIDs are widely prescribed as symptomatic treatment for various clinical conditions, e.g., acute pain, chronic inflammatory and degenerative joint diseases, etc. Looking more closely, in consideration of the clinical and public health implications and their widespread use, it is important to confirm the previously observed association between NSAID use and AF [16] .
Although previous studies have investigated the role of NSAIDs on AF, most were conducted in general populations. Limited studies have evaluated the adverse effects of NSAIDs on AF in a middle-aged population, especially Asian populations. To extend our understanding of this issue, this study presents the findings of a nested case-control study designed to elucidate the effects of NSAID use on AF occurrence in a middle-aged population using a large nationwide population-based cohort in Taiwan.
Methods

Data source
This study used data derived from three different Longitudinal Health Insurance Databases (LHIDs) comprised of medical claims data, which are part of the National Health Insurance Research Database (NHIRD) in Taiwan. In detail, the NHIRD includes demographic characteristics, outpatient visits and inpatient claims data, prescription records and disease diagnoses for approximately 99% of the entire population of 23 million people in Taiwan [17] . The LHIDs were generated by randomly selecting one million enrolees from the National Health Insurance (NHI) programme in 2000 (LHID 2000) , 2005 (LHID 2005 ) and 2010 (LHID 2010), separately. As a result, data from a total of three million enrolees were investigated in this study. All medical claims data in the LHIDs from January 1, 2001 to December 31, 2013 were included, accordingly. The study protocol was approved by the Institutional Review Board of the National Health Research Institutes, Taiwan.
Cases of atrial fibrillation and matched controls
The incident cases of AF were defined as individuals aged 45 years and older in 2001 with medical claims (either a onetime hospitalization or at least two or more outpatient visits within one year) for AF (ICD-9-CM codes: 427.31) during the study period. The date of the first medical claim record for AF was identified as the index date. We applied three different matching algorithms: (1) matching by index year, age and gender; (2) matching by index year, age, gender and four related diseases; and (3) matching by disease risk score (DRS) at the fourth decimal point by accounting for potential confounding factors (Table S1 ). In detail, the DRS, which in this case was a patient's predicted probability of developing AF, was estimated using logistic regression [18] and calculated based on the individual covariate values multiplied by the regression coefficients. All of the considered covariates (as shown in Table S1 ) in the year prior to the index date were included in the logistic regression model without variable selection. We selected the second matching algorithm for subsequent analyses in this study. Specifically, for each case, we randomly selected one control who did not have any AF diagnosis at the time that the matched case was first diagnosed with AF. The controls were matched with the case by age (the same birth year), sex, type 2 diabetes mellitus (T2DM), hypertension, congestive heart failure (CHF), osteoarthritis, and index year. Matched controls were assigned the same index date as their matched cases. Of note, among cases, participants were excluded if they were ever diagnosed as having AF or valvular heart disease (VHD) prior to 2004. For both cases and controls, we excluded participants taking part in the NHI programme for less than one year before the index date.
Utilization of nonsteroidal anti-inflammatory drugs (NSAIDs)
A list of NSAIDs was identified from prescription records in the LHIDs, including: the different medication components, time of prescription, and duration of drug supply and dosage, individually. Specifically, NSAIDs were classified as follows: (1) 
NSAID exposure
We investigated the effect of long-term NSAID use on the development of AF. The definition of exposure to NSAID use in this study was as follows. First, participants exposed to NSAIDs were defined as 'users' if they had at least one day of an NSAID supply within 365 days prior to the index date. Next, among the users, we defined participants as 'current users' if they were exposed to NSAIDs within 30 days prior to the index date, or as 'past users' if they were exposed to NSAIDs within 31-365 days (but not within 30 days) prior to the index date. Furthermore, current users were defined as 'new users' if they were first exposed to NSAIDs during 30 days prior to the index date, but not exposed to NSAIDs between 31 and 365 days prior to the index date, or 'continuous users' if NSAIDs were started between 31-365 days prior to the index date. Participants were defined as 'nonusers' if no NSAID was prescribed within 365 days prior to the index date [1, 11] .
Adjustment of potential confounding factors
The list of potential confounders considered in this study included medical comorbid disorders (anaemia, coronary heart disease, myocardial infarction (MI), heart failure, cerebrovascular disease, coronary artery disease, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease, malignant neoplasm, peripheral vascular disease, Parkinson's disease, rheumatoid arthritis and renal failure), concomitant medications (antidepressants, anxiolytics, anticonvulsants, antihypertensives, bisphosphonates, benzodiazepines, inhaled glucocorticosteroids, oral glucocorticosteroids, hormone replacement therapy), and healthcare utilization within one year prior to the index date (both outpatient visits and hospitalizations) [11, 19] .
Data analysis
Descriptive statistics of the AF cases and matched controls (e.g., demographic and clinical characteristics, comorbid medical disorders, concomitant medication use, and healthcare utilization) were summarized as counts and percentages, or as mean and standard deviation (SD). To compare the distribution of demographic and clinical characteristics between the AF cases and matched controls, a chi-square test was used for testing discrete variables and the Student's t-test was used for testing continuous variables. Conditional logistic regression analyses (with and without covariate adjustment) were performed to determine the association of NSAID use (overall, selective and non-selective NSAIDs, individually), defined daily dose (DDD) of NSAIDs, which was defined as 'the assumed maintenance dose per day for a drug used for its main indication', and number of prescriptions, respectively, with AF. We further examined the various exposure statuses, different classes, and each individual drug effect of the NSAIDs. If participants took two or more classes of NSAIDs at the same time, we defined those participants as combined users. The covariates that were adjusted for in the models are listed above.
We declared P-values less than 0.05 as statistically significant. All analyses were carried out using SAS version 9.2 for Windows (SAS Institute, Cary, NC).
Results
A total of 57 058 participants (28 529 AF cases and 28 529 matched controls) were included in the study. Among them, there were 21 416 participants from LHID 2000 (10 708 AF cases and 10 708 matched controls), 22 014 participants from LHID 2005 (11 007 AF cases and 11 007 matched controls), and 17 808 participants from LHID 2010 (8904 AF cases and 8904 matched controls), respectively. Figure 1 depicts the detailed flow chart for identifying participants included in the study cohort. Of note, we excluded participants who were in two out of the three LHID datasets (n = 2090). The distributions of demographic and clinical characteristics, concomitant medication use, and healthcare utilization in LHID2000, LHID2005, LHID2010 and the three LHID combined datasets are presented in Table S2 and Table 1, respectively.
In addition, we applied three matching algorithms as presented in Table S1 . The results were comparable across the different matching algorithms. Given this finding, we used the dataset that was created from individual disease matching; that is, the controls were matched with each AF case by age (the same birth year), sex, T2DM, hypertension, CHF, osteoarthritis, and index year, to perform the subsequent analyses, and reported the results. Table 2 presents the association between NSAID use on the risk of AF. Compared to non-users, participants with NSAID use had a positive association with AF in the LHID combined dataset [adjusted odds ratio (AOR) = 1.18, 95% confidence interval (CI): 1.14- Table 2 ). In addition, when we treated 3 months prior to the index date as the latent period in this study and repeated the analyses accordingly, similar results were observed (Table S3) .
When further assessing the effects of different classes of NSAIDs on the risk of AF (Table 3) , we found that participants taking non-selective NSAIDs had a significantly elevated risk of AF (AOR = 1.18, 95% CI: 1.13-1.23) as did participants with a combined use of selective and non-selective NSAIDs (AOR = 1.30, 95% CI: 1.21-1.39) in the LHID combined dataset, but this was not true for participants taking selective NSAIDs only. We also examined the effects of each individual NSAID on AF among participants in LHID 2000, LHID 2005 and LHID 2010, separately. The results suggest that various individual NSAIDs might have a different degree of adverse effect on the risk of AF (Tables S2-S4 ). Instead of comparing nonselective NSAIDs and selective COX-2 inhibitors, we further grouped the drugs by more selective for COX-1, intermediate COX-2 selectivity, and high COX-2 selectivity, separately. Similar results were found as shown in Table 3 . When investigating defined daily dose (DDD) and number of prescriptions, respectively, no dose-response effects were found for the use of NSAIDs (Table 4) . 
Discussion
In this nationwide population-based case-control study, our results provide supportive evidence that NSAID use is associated with increasing incidence of AF in a middle-aged Taiwanese population. Importantly, positive associations between NSAID use and AF were found in each of the three independent LHID datasets and in the combined LHID dataset.
Figure 1
Flow chart of inclusion/exclusion criteria for study populationNote: AF, atrial fibrillation; DM, diabetes mellitus; HT, hypertension; CHF, congestive heart failure; OA, osteoarthritis When classifying NSAIDs as non-selective NSAIDs, selective NSAIDs and combined NSAIDs, similar adverse effects of NSAID use on AF were observed among non-selective NSAID and combined NSAID users.
Findings from this study are in line with results reported in previous studies [1, 20, 21] . For instance, Schmidt et al. have suggested that NSAID use is positively associated with the risk of AF in a Danish population-based study [11] . Their [12] . It is known that NSAIDs inhibit cyclooxygenase isozymes (e.g., COX-1 and COX-2) and block biosynthesis of prostanoid (PG). As such, NSAIDs decrease total renal perfusion and redistribute renal blood flow, which may increase the risk of AF through adverse renal effects via fluid retention, electrolyte disturbances, and blood pressure destabilization. Furthermore, these changes may induce blood pressure elevation due to expansion of plasma volume, then increased left atrial (LA) pressure, LA stretch, consequently increased peripheral resistance, [22, 23] and fluctuation of serum potassium as a result of decreased potassium excretion in the distal nephron, which then triggers AF [24] . The strengths of this study include, first, the use of three independent datasets, specifically, LHID 2000, LHID 2005 and LHID 2010, to investigate the association between NSAID use and AF, in each of which we found similar results. These findings indicate the robustness of the observed adverse effects of NSAIDs on AF. Second, most studies have Figure 2 Risk of atrial fibrillation in relation to NSAID use among participants in the LHID combined dataset, stratified by age, gender and various clinical characteristics.
a Adjusted variables included: medical comorbid disorders (chronic kidney disease, myocardial infarction, sleep apnoea, hyperthyroidism, ankylosing spondylitis, systemic lupus erythematosus, rheumatoid arthritis, gout, coronary artery disease and valvular heart disease), and concomitant medication use (antidepressants, anticonvulsants, anxiolytics, benzodiazepines, bisphosphonates, glucocorticosteroids and hormone replacement therapy)
examined the associations between NSAID use and AF in general populations. While the majority of these previous studies have investigated the adverse effects of NSAID use on AF in European general populations, limited studies have reported its adverse effects on AF in Asian populations. This study is one of only a limited number of studies to evaluate the adverse effect on AF in Asian populations, especially in a middle-aged Asian population. Third, we applied three different matching algorithms and repeated the analyses using LHID 2000, which could serve as a sensitivity analysis. Of note, similar results were observed no matter which matching algorithms were employed, which provided supportive confirmatory evidence in a single study. Several limitations should be noted. First, we were not able to estimate the effect of over-the-counter NSAID use. However, this misclassification is likely to be non-differential and lead to bias towards the null and an underestimation of risk. Second, we only examined the adverse effects of NSAID use on AF in Taiwanese study participants. It would be interesting to confirm these results in other ethnic populations, particularly in other Asian populations. Third, information on potential confounding factors such as smoking, alcohol and obesity are not available in the NHIRD. Therefore, we employed clinical proxy surrogates, for example, T2DM and hypertension for obesity, to adjust for those unmeasured confounding risk factors. However, it was likely that residual confounding effects could still exist due to those unmeasured variables. Fourth, the underlying pathophysiology of adverse effects of NSAID use on AF is still not well understood and merits further investigation. Fifth, the definition of NSAID use was somewhat limited, even though we defined NSAID use based on previous publications [1, 11] . For instance, subjects with only one day of use were classified as users. However, the influence of this on our results should be limited as the percentage of subjects with only one day of NSAID use was small in this study.
In summary, the findings from this study indicate that NSAID use increases the risk of AF among middle-aged adults in an Asian population. Based on these findings, it will certainly be important for physicians who prescribe NSAIDs to do so cautiously, especially among those at high risk for AF. Benefits and risks of NSAID use should be carefully evaluated when delivered in clinical practice. The underlying mechanisms associated with our findings deserve further investigation. 
